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Introduction

Results

Osteoporosis is a disease of the skeletal system in which bone is compromised
leading to increased risk of fracture [1]. One in three women will experience a fracture
due to osteoporosis in their lifetime, with postmenopausal women being the most
susceptible [1]. One of the main intrinsic factors that increase the risk of osteoporotic
fracture in postmenopausal women is discontinuities in the microarchitecture of bone
[1]. Since trabecular bone is 3-4 times more metabolically active than cortical bone
[2], distal femur trabecular thickness was used as the parameter for bone quality in
this study. Data suggested that 25% of Americans reported insufficient sleep (>6 hr
over more than 15 days/month) [3]. Heightened adverse physiological effects,
including lowered BMD and decreased bone quality, resulting from sleep deprivation
were identified in menopausal females [4], therefore, this study aimed to incorporate
sleep-deprivation as a variable in bone health.
Bisphosphonates, such as Zoledronate, are a common
treatment for osteoporosis. Zoledronate attempts to
inhibit osteoclastic activity by blocking a portion of the
mevalonate pathway through the inhibition of farnesyl
pyrophosphate synthase which restricts the prenylation
of certain GTPases [5]. The purpose of this study was to
evaluate the consequences of sleep deprivation on bone
metabolism with and without the protective effects of
Figure 1: Zoledronate
Zoledronate in sleep-deprived, estrogen-deficient rats.

The purpose of this study was to evaluate the trabecular
thickness using a commonly prescribed bisphosphonate in
attempts to explore potential advantages in sleep-deprived,
ovariectomized rats. An analysis of covariance (ANCOVA) model
was used to predict trabecular thickness with treatment group as
a main factor and housing as a covariate, including a factor for
the interaction of treatment and housing. There was a significant
treatment and housing effect on trabecular thickness (each
p<0.0001), with the interaction also being a significant
(p=0.0078), suggesting treatment affected mean trabecular
thickness differently by which housing rats were in. Overall the
model achieved an R² of 0.612. Assumptions of normality of the
residuals were not investigated further, but a non-parametric
Kruskal Wallis test was run to verify the pattern of the ANCOVA
results (p<0.001). Further investigation using Tukey (confirmed
with Bonferroni) multiple comparisons tests revealed there were
significant differences between SDZ and C (p<0.0001), SD and
SDZ (p<0.0001), and the Z and SDZ groups (p<0.0001).

Discussion

Methodology
Ovariectomized Wistar female rats (n=31) were received from the Wistar Institute
and given a 1-week adjustment period in standard conditions. Standard conditions
included a 12-hour light/dark cycle and food and water provided ad libitum. The rats
were randomly assigned into 4 groups including a Control (C, n=4), Zoledronate (Z,
n=9), Sleep-deprived (SD, n=9), and Sleep-deprived + Zoledronate (SDZ, n=9). The
C and SD groups were given a one-time intravenous injection of 0.45mL of 0.9%
saline. The Z and SDZ group received a one-time intravenous injection of 50ug/kg
body weight of 10% Zoledronate. After the injection, the 5-week protocol was
started. The C and Z groups were kept in standard housing. However, the SD and
SDZ groups were housed in MMP tanks (Figure 2) which prevented sleep for 18
hours, then moved to the sleep chambers for 6 hours. After 5 weeks, the rats were
exsanguinated and tibiae and femora were collected, wrapped in saline-soaked
gauze, stored at -80°C, and shipped to Novartis Institute for Biomedical Research
where high-resolution micro-computed tomography scans were performed (Figure
2). Statistical analysis included ANOVA, Tukey, Bonferroni, and Kruskal Wallis tests
as well as the creation of an interaction graph using ANCOVA in R Studio.
Figure 2: Modified Multiple Platform Tank

Figure 4: The average distal femur trabecular thickness and SE of the C, Z,
SD, and SDZ groups. The SDZ group had a significant difference in distal
femur trabecular thickness compared to the Control group (75.5 and 67.25
microns, respectively; p<0.0001).

Using more robust statistical analyses on previously gathered
data has revealed a possible physiological interaction between
the amount of sleep and the use of Zoledronate. Further studies
are needed to determine the mechanism behind the
physiological interaction, but results could have a profound
impact on the use of Zoledronate in modern society where many
people are getting less sleep because of work demands.
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location of µCT
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Figure 5: Interaction between the treatment and the amount of sleep the
rats received (p=0.0078; R²=0.612)

